Mr. Francois Roberge reports

LSL PHARMA GROUP ANNONCES $1.4 MILLION OF NEW ORDERS FROM INTERNATIONAL CLIENTS AND COMPLETION OF STERI-MED PHARMA'S PHASE 1 PRODUCTION SCALE UP

LSL Pharma Group Inc. has secured $1.4-million in new orders from international clients, and has completed the initial phase of production scale-up at its Steri-Med Pharma facility. The initial phase of production scale-up has contributed to more than double the plant capacity compared with 2023 levels, and enabled Steri-Med to win new international contracts for its existing products.

"We are excited with the progress made to date at our Steri-Med facility. Historically, production capacity has been a limiting factor of growth for Steri-Med's revenues. Following investments made thus far in 2024, we have more units available for non-Canadian sale," commented Francois Roberge, president and chief executive officer of LSL Pharma. "Following the sale of more than 500,000 units of our Erythomycin one-gram product to the U.S. [United States] over the last year, international demand for Steri-Med's sterile ointment products is growing. Recently, we have been successful in opening new sales channels for Steri-Med's products, which contributed to LSL Pharma securing $1.4-million of new orders over the recent months."

The second phase of production scale-up will include the installation of a new fully automated sterile ointment production line. The second line is expected to be delivered during the first quarter of 2025 and to be operational in early 2026, following installation and validation.

"Once operational, the second line is expected to increase Steri-Med's production capacity fivefold compared to our current 1.2-million-unit production capacity, as well as free up capacity to support the development of Steri-Med's first-to-market generic product pipeline," said Mr. Roberge.

About LSL Pharma Group Inc.

LSL Pharma Group is an integrated, Canadian-based pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceuticals, as well as natural health products in solid and liquid dosage forms.

We seek Safe Harbor.